BioArctic to Initiate Next Cohorts In Exidavnemab Phase 2a Study After Positive Safety Review

The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blinded, placebo-controlled study to evaluate the safety and tolerability of exidavnemab and its pharmacokinetic profile.